HCC: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy
Study Details
Study Description
Brief Summary
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide, and HCC is more frequently observed in Asia, including South Korea. As HCC is often accompanied by chronic hepatitis B or C virus and liver cirrhosis, treatment of HCC consider not only the tumor but also various factors such as liver function and the patient's performance status. Local treatment and surgery are possible in the early stages of HCC. However, it has a high recurrence rate even after curative surgeries due to underlying cirrhosis and the tumor microenvironment.
Although several studies have investigated gene mutations and differences in treatment response in advanced HCC through next-generation sequencing (NGS), studies on transcriptome analysis of advanced HCC through RNA-sequencing are hard to find, with a need for future research into precise classification and clinical significance of HCC based on multi-omics data.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
to establish multi-omics data and discover biomarkers highly associated with treatment response in HCC patients
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| intervention atezolizumab + bevacizumab |
Drug: atezolizumab plus bevacizumab
1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
|
Outcome Measures
Primary Outcome Measures
- collected tumor samples [through study completion, an average of 3 years]
tumor samples from patients with hepatobiliary cancers (incidence of genetic alteration, association with treatment response and survival duration)
- collected blood samples [through study completion, an average of 3 years]
blood samples from patients with hepatobiliary cancers (incidence of genetic alteration, association with treatment response and survival duration)
Secondary Outcome Measures
- Multi-omics analysis [3 years]
Multi-omics analysis to further subtype and find therapeutic targets of HCC
- Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC [3 years]
Molecular biomarker associated with overall survival, progression-free survival and objective response rate in patients who receive atezolizumab plus bevacizumab
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study.
-
Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests.
-
Patients who underwent an NGS test with advanced HCC tissues
-
Patients who are scheduled to receive systemic treatment
-
Patients with measurable lesions based on RECIST v1.1
-
ECOG performance status 0 or 1
-
Patients with a life expectancy of at least three months
Exclusion Criteria:
-
Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure
-
Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form
-
Those who are assessed as not suitable for this study, at the discretion of the researcher
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHA Bundang Medical Center | Seongnam-si | Gyeonggi-do | Korea, Republic of | 13496 |
Sponsors and Collaborators
- CHA University
Investigators
- Principal Investigator: Hongjae Chon, MD,PhD, Principal Investigator
Study Documents (Full-Text)
None provided.More Information
Publications
- Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007 Jan;45(1):42-52.
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
- Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010 Feb;30(1):35-51. doi: 10.1055/s-0030-1247131. Epub 2010 Feb 19. Review.
- Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
- Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4. Review.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.
- 2021-11-019